Rubicon Research Quarterly Results for Trading Insights
In Mar 2026, Rubicon Research (RUBICON) reported revenue ₹517 Cr and net profit ₹77 Cr — revenue +44.4% YoY. View RUBICON yearly price range for the annual high/low range and current price position.
RUBICON Quarterly Results — Revenue, Profit & EPS Highlights
Rubicon Research latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Rubicon Research share price screener.
- Revenue of ₹517 Cr in Mar 2026 (-4.3% vs Jun 2026, +44.4% vs Mar 2025)
- Net Profit of ₹77 Cr in Mar 2026 (-9.4% vs Jun 2026, +113.9% vs Mar 2025)
- EBITDA of ₹121 Cr in Mar 2026 (-10.4% vs Jun 2026)
- Operating Margin of 23.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹4.68 in Mar 2026 (-8.8% vs Jun 2026)
Rubicon Research Quarterly Results — Revenue, EBITDA, Net Profit & EPS
RUBICON quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 517 | 540 | 413 | 358 | 353 | -4.3% | 44.4% |
| Net Profit (₹ Cr) | 77 | 85 | 54 | 36 | 43 | - | - |
| EBITDA (₹ Cr) | 121 | 135 | 95 | 73 | 80 | - | - |
| EPS (₹) | 4.68 | 5.13 | 3.49 | 2.37 | 2.81 | - | - |
| Operating Margin (%) | 23.0% | 24.0% | 23.0% | 20.0% | 22.0% | - | - |
RUBICON Share Price Trend — 1-Year Movement Across Quarterly Results
Rubicon Research 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse RUBICON promoter holding to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
RUBICON vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Rubicon Research latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores